Arthritis news. Anytime. Anywhere.

Cassie and Friends needs your voice for the upcoming BC 2017 Election

Calling on the BC Government to save and change the lives of children living with systemic juvenile idiopathic arthritis.

Cassie and Friends BC Election ImageJuvenile idiopathic arthritis (JIA) affects 24,000 infants to teens in BC and Canada, or 3 in every 1,000, making it one of the most common causes of chronic disability in children. Ten to 20 percent of children living with JIA have systemic juvenile idiopathic arthritis (sJIA), a severe and potentially life-threatening form of the disease. Both JIA and sJIA can be devastating and come with high financial, family and societal burdens.

In partnership with Arthritis Consumer Experts, Cassie and Friends Society is leading a call for the BC Government to drastically improve the outlook of children with sJIA by allowing reimbursement coverage for canakinumab for children who need it. For children who do not respond to other treatments, canakinumab can prevent progression of the disease and disease symptoms.

Cassie and Friends is urging all parties running for public office in British Columbia to make juvenile arthritis and canakinumab reimbursement access a health priority during the upcoming provincial election on May 9. You can help by sharing your story or sending an email or letter to your candidate. Together, we can help improve the lives of children living with arthritis!

What can you do? Continue reading

On election day, how will you vote? The BC Election is scheduled for May 9.

The next general election in British Columbia is scheduled for May 9, 2017. What change would you want to see?

Arthritis affects 1 in 5 British Columbia residents, so healthcare to treat the more than 100 different types of the disease is extremely important to the more than 600,000 British Columbians living with the disease. Any party that wishes to become government needs to consider these constituents. To help the parties understand this, Arthritis Consumer Experts (ACE) sent a questionnaire to the candidates of the 2017 BC Provincial Election.

The questionnaire asked the following questions: Continue reading

Health Canada approves sarilumab (Kevzara®) for the treatment of rheumatoid arthritis

Approved stamps for sarilumab for rheumatoid arthritis

Image courtesy of karate at FreeDigitalPhotos.net/

Sarilumab (Kevzara®) is now approved in Canada to treat moderate to severely active rheumatoid arthritis

Health Canada has approved a new treatment for Canadians with moderate to severely active rheumatoid arthritis. Sarilumab (Kevzara®) was issued its Notice of Compliance on January 12, 2017. Click here to view Health Canada’s Summary Basis of Decision.

Sarilumab (Kevzara®), an interleukin-6 receptor antagonist, has been approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate reponse or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Continue reading

Attention ACE members with psoriatic arthritis and psoriasis

An image of PureCare Herbal CreamHealth Canada has issued a warning about ingredients in PureCare Herbal Cream 

PureCare Herbal Cream, advertised as a natural treatment for eczema and psoriasis in children and babies, may pose serious health risks.

Health Canada testing confirmed the presence of a prescription steroid (clobetasol propionate) and another ingredient (phenoxylethanol) not declared on the product label. These ingredients may cause health effects ranging from skin irritation and dehydration to increased blood pressure. Continue reading

Let BC PharmaCare hear “Your Voice” on sarilumab

Stickman with megaphone calling for Your Voice patient inputBC PharmaCare is looking for your input on sarilumab for the treatment of rheumatoid arthritis

Sarilumab (Kevzara™) is a fully human monoclonal antibody that targets IL-6, a protein central to the development of the signs and symptoms of rheumatoid arthritis. Sarilumab can be used alone or in combination with methotrexate or other traditional disease-modifying antirheumatic drugs (DMARDs). It is given by subcutaneous (under the skin) injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program.  Continue reading

Arthritis Broadcast Network named one of Feedspot’s Top 40 Arthritis Blogs

Top 40 Arthritis Blog BadgeArthritis Broadcast Network (ABN) – powered by Arthritis Consumer Experts – All your arthritis news and information. All the time. Thanks to our fans, our most recent Facebook Live event reached over 23,000 people in just three days!

Arthritis Broadcast Network is honoured to be named one of the top 40 arthritis blogs and websites for people living with arthritis by Feedspot. Rankings are based on the following criteria: Continue reading